Observe The Curative Effect Of Entecavir Monotherapy And Combined With Recombinant Human Interferon ?-2b For Treating HBeAg Positive Chronic Hepatitis B

Objective To study the therapeutic effect of combining with recombinant human interferon alfa-2b(cIFN ?-2b)in patients with chronic hepatitis B(CHB)who underwent HBe Ag clearance for more than 24 weeks with entecavir(ETV)antiviral therapy.Methods The patients were randomly divided into two groups: the single drug group continued ETV treatment.The combined group was treated with cIFN?-2b on the basis of ETV for 48 weeks.According to the group time(0 weeks),12 weeks,24 weeks,36 weeks,48 Week time node for blood test.Measurement data using t test,count data using ?2 test.Results In this study,68 patients were enrolled in the study group,32 patients in the monotherapy group and 36 patients in the combined group.Six patients withdrew(8.8% of the follow-up),62 patients were followed up for 48 weeks,30 patients in the monotherapy group and 32 patients in the combined group.There was no significant difference in baseline characteristics between the monotherapy group and the combined group(P>0.05).At the end of the study,the incidence of HBV DNA <100 IU/m L in the monotherapy group and the combined group was 90.0%(27/30)vs 93.8%(30/32),the difference was not statistically significant(P=0.940);the incidence of HBsAg<250IU/mL was 33.3%(10/30)vs 59.4%(19/32),the difference was statistically significant(P=0.040);the HBeAg clearance and seroconversion rate,HBeAg decrease and ALT <45U/L were higher in the combined group than in the monotherapy group,but the difference was not statistically significant(P>0.05).The incidence of HBeAg clearance and seroconversion in HBsAg <250IU / mL group and HBsAg>250IU/mL group was 41.4%(12/29)vs 12.1%(4/33)at the end of the study,and the difference was statistically significant(P=0.019).At the end of the study,the incidence of baseline HBsAg <250 IU/mL in HBeAg clearance and seroconversion group and HBe Ag untransformed group was 56.3%(9/16)vs 26.1%(12/46),and the difference was statistically significant(P=0.028);The baseline HBeAg levels in the HBeAg clearance and seroconversion group and the HBeAg untransformed group were(20.30± 17.10)PEI U/mLvs(49.98±44.44)PEI U/mL,and the difference was statistically significant(P=0.015).HBeAg clearance and seroconversion was associated with baseline HBsAg <250 IU/mL(P=0.028,r=0.269).Conclusion A higher incidenc of HBsAg <250 IU/mL was achieved in patients with HBe Ag-positive CHB combined with cIFN ?-2b for 48 weeks after ETV treatment.HBsAg<250 IU/mL and HBeAg levels were predictive of HBe Ag clearance and seroconversion.HBe Ag clearance and seroconversion was associated with baseline HBsAg <250 IU/mL after antiviral therapy.